Chronic Bacterial Prostatitis
Conditions
Keywords
Bacterial prostatitis, CBP, Levofloxacin, Prulifloxacin
Brief summary
The aim of the study is to assess the efficacy and safety of prulifloxacin in comparison to levofloxacin in the treatment of patients affected by CBP.
Detailed description
This is a randomized, double-blind, levofloxacin controlled, parallel group, multicentre, international, prospective study. The patients will be enrolled in the study and will be randomized to prulifloxacin or levofloxacin. Patient enrolment will be competitive. The present study is planned to verify the microbiological and the clinical efficacy of a 28-day treatment period with prulifloxacin 600 mg in comparison with 28-day treatment period with levofloxacin 500 mg, both administered once daily, in patients with CBP. Safety and tolerability of a 28-day treatment period with prulifloxacin 600 mg will be also evaluated in comparison to levofloxacin 500 mg. Levofloxacin 500 mg tablets has been selected as treatment comparator because it represents the drug of choice authorised for the treatment of CBP. Consequently, the dosage regimen to be administered to the patients is consistent with that reported in the relevant SPC.
Interventions
DRUGPrulifloxacin 600 mg
Oral administration of one tablet once daily for 28 days of prulifloxacin 600 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.
Oral administration of one tablet once daily for 28 days of levofloxacin 500 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.
Sponsors
Hippocrates Research
Aziende Chimiche Riunite Angelini Francesco S.p.A
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
The present study will be performed in double blind condition. Consequently, during the study, neither the Investigator nor the patient will be aware of the treatment assigned.
Intervention model description
Double-blind, levofloxacin controlled, multicentre, international, prospective study.
Eligibility
Sex/Gender
MALE
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
1. Male between 18 and 50 years of age (limited included) with no limitation of race. 2. Patients presenting symptoms of prostatitis for at least 3 months. 3. Laboratory evidence of CBP at Visit 0 (Screening), assessed by Meares&Stamey fourglass test and defined as: 1. VB3 or EPS specimen containing ≥10\^2 colony-forming units/ml of pathogen/s if the VB2 specimen is sterile; or 2. VB3 or EPS specimen containing ≥10\^2 colony-forming units/ml of pathogen/s different from any present in the VB2. 4. Medications for chronic prostatitis and/or medications that may affect bladder or prostate function (including but not limited to hormone therapy, anticholinergic or alpha blocker) must be discontinued at least 7 days before study drug intake. 5. Patients legally capable to give their consent to participate the study, and available to sign and date the written informed consent.
Exclusion criteria
1. Known hypersensitivity or allergy to antibacterial fluoroquinolones or to any components of the study medications. 2. Pathogen/s resistant to the study drugs at Visit 0 (Screening). 3. Suspicion for prostatic cancer, neurogenic bladder, Benign Prostatic Hypertrophy (BPH), bladder neck obstruction or urethral stricture. 4. Body Mass Index (BMI) \< 16 kg/m\^2. 5. Immunocompromised patients. 6. Signs or symptoms or clinical documentation for concurrent infections (including but not limited to sexually transmitted infections) and/or neoplasm. 7. Clinically significant abnormalities on physical examination, vital signs, ECG, laboratory tests at Visit 0 (Screening Visit). 8. Significant liver disease, defined as known active hepatitis or elevated liver enzymes \> 3 times the upper boundary of the normal ranges. 9. Value of creatinine outside the normal ranges and judged clinically relevant by Investigator. 10. History of cardiac disease, including but not limited to myocardial infarction, heart failure, cardiomyopathy, cardiac hypertrophy, cardiac arrhythmias, bradycardia, cardiac conduction abnormalities, long QT syndrome. 11. Value of electrolytes (sodium, potassium, calcium, magnesium, chloride) outside the normal ranges and judged clinically relevant by Investigator. 12. Patients under treatment with medications that may cause increase of the QT interval. 13. History of tendinopathy. 14. Patients with latent or known deficiencies for the glucose-6-phosphate dehydrogenase, or with hereditary problems of galactose intolerance or the Lapp lactase deficiency or glucose-galactose malabsorption. 15. Recent or past history of psychiatric illness or epilepsy. 16. Treatment with antibiotics or antibacterials within 2 weeks before study drug start intake. 17. Treatment with experimental drugs (prulifloxacin or levofloxacin) or other fluoroquinolones within 4 weeks before study drug start intake. 18. Diabetic patients in treatment with oral hypoglycemic drugs and insulin. 19. Patients under treatment with corticosteroids or Non-Steroidal Antiflammatory Drugs (NSAIDs). 20. Concomitant treatment with xanthines or anticoagulant drugs or drugs producing hypokalemia or diuretics. 21. Positive history for drugs and alcohol abuse. 22. Inability to comply with the protocol requirements, instructions or study-related restrictions (i.e. uncooperative attitude, inability to return for study-visits, improbability of completing the clinical study). 23. Vulnerable subjects (i.e. persons kept in detention). 24. Subject involved in the conduct of the study (i.e. Investigator or his/her deputy, first grade relatives, pharmacist, assistant or other personnel). 25. Participation to an interventional clinical trial within 3 months prior to Visit 0 (Screening Visit).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Eradication of bacterial growth | 7 days after the EOT | Eradication defined as absence of bacterial growth as \<10\^2 CFU/ml in voided bladder 3 (VB3) or expressed prostatic secretion (EPS) after 7 days from the End Of Treatment (EOT). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Eradication of bacterial growth | 3 months after the EOT | Eradication defined as absence of bacterial growth as \<10\^2 CFU/ml in voided bladder 3 (VB3) or expressed prostatic secretion (EPS) after 3 months from the EOT. |
| Reduction in National Institute of Health - Chronic Prostatitis Symptom (NIH-CPSI) | Screening - 7 days after the EOT | Reduction of total score in NIH-CPSI after 7 days from the EOT in comparison to the screening. |
| Frequency of treatment-related adverse events | 6 months | Monitoring of the frequency of adverse events, physical examination, vital signs, ECG, laboratory analyses. |
Countries
Greece, Italy
Outcome results
None listed